Indication
Esbriet is indicated in adults for the treatment of idiopathic pulmonary fibrosis.
Loading your page…
Loading your page…
Idiopathic Pulmonary Fibrosis;Lung Diseases;Respiratory Tract Diseases
Marketing Authorisation Holder: H.A.C. Pharma
EMA Authorisation: 28/02/2011
INN: pirfenidone
AI Drug & Interaction Analysis
Free account required
Ask Osler about Esbriet: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.